NSD2 and cancer: Ultimately, our results suggest that the RAS pathway through MEK activation controls functional enhancers in cancer cells and that overexpression of NSD2 causes the spread of the H3K36me2 mark from these enhancers into neighboring areas that have low levels of H3K27me3 further activating the expression of genes embedded in these regions (Fig. 6d).